Theratechnologies rises after FDA nod for HIV treatment's IV use

Theratechnologies

03/10/2022 20:43

** U.S.-listed shares of biopharmaceutical co
Theratechnologies Inc  THTX.O  rise as much as 16.5% to $2.76 
    ** Shares rise after co announces FDA approval of its drug
for Human Immunodeficiency Virus-1 (HIV-1) infection in adults,
Trogarzo, for intravenous (IV) push method  urn:newsml:reuters.com:*:nGNX4spsCB
    ** FDA originally approved Trogarzo in 2018 to be
administered intravenously as a single loading dose followed by
a 15-minute maintenance dose every two weeks
    ** With the IV approval, maintenance dose can be
administered as an undiluted IV push over 30 seconds, cutting
down treatment time
    ** Co says Trogarzo is also being studied for intramuscular
injection administration
    ** Including session's gain, THTX is flat YTD 
 (Reporting by Nandhini Srinivasan in Bengaluru)
 ((Nandhini.srinivasan@thomsonreuters.com))